Cost-effectiveness of the BRECONDA decision aid for women with breast cancer

results from a randomized controlled trial

Bonny Parkinson, Kerry Sherman*, Paul Brown, Laura-Kate E. Shaw, John Boyages, Linda D. Cameron, Elizabeth Elder, Thomas Lam

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)


Objective: To report on the cost-effectiveness of BRECONDA (Breast RECONstruction Decision Aid), a web-based decision aid to facilitate decisions regarding breast reconstruction surgery, with usual care for women with breast cancer. Methods: The economic evaluation was conducted alongside a randomized controlled trial. Women diagnosed with breast cancer or ductal carcinoma in situ and eligible for breast reconstruction following mastectomy were randomized to access BRECONDA for 6 months + usual care (n = 106) or usual care (n = 116) and were assessed at baseline preintervention, and then 1-month and 6-months post-randomization. Decisional conflict, satisfaction with information, decisional regret, and utilities were assessed by using maximum-likelihood linear mixed effects models. Costs included the fixed costs of BRECONDA, health care provider time, and health care resource use. Nonparametric bootstrapping was used to estimate incremental cost-effectiveness ratios. Results: BRECONDA resulted in significantly less decisional conflict and greater satisfaction with information over time. Quality-adjusted life years did not differ between participants who received the decision aid compared with usual care. The cost of BRECONDA was estimated to be small (AUD$10) relative to other health care interventions and resulted in decreased health care costs overall (AUD$764). Based on the point estimates, the decision aid was more effective and less costly (dominant) for all measures of effectiveness. It was estimated that the decision aid has an 87% probability of being cost-effective at $60 000 per quality-adjusted life year gained. Conclusions: The BRECONDA web-based intervention designed to facilitate decisions regarding breast reconstruction surgery is likely to be cost-effective compared with usual care for women with breast cancer.

Original languageEnglish
Pages (from-to)1589-1596
Number of pages8
Issue number6
Early online date5 Apr 2018
Publication statusPublished - Jun 2018


  • breast cancer
  • cost-effectiveness
  • decision aid
  • oncology
  • quality adjusted life years
  • Cancer

Fingerprint Dive into the research topics of 'Cost-effectiveness of the BRECONDA decision aid for women with breast cancer: results from a randomized controlled trial'. Together they form a unique fingerprint.

  • Cite this